TBRG1

Summary

TBRG1 (transforming growth factor beta regulator 1, HGNC:29551) is a protein-coding gene on chromosome 11q24.2, encoding Transforming growth factor beta regulator 1 (Q3YBR2). Acts as a growth inhibitor.

Involved in several processes, including DNA replication; protein localization to nucleoplasm; and protein stabilization. Located in nucleoplasm.

Source: NCBI Gene 84897 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 73 total — 1 likely-pathogenic
• MANE Select transcript: NM_032811

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29551
Approved symbol	TBRG1
Name	transforming growth factor beta regulator 1
Location	11q24.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ14621, TB-5, NIAM
Ensembl gene	ENSG00000154144
Ensembl biotype	protein_coding
OMIM	610614
Entrez	84897

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 6 protein_coding, 3 nonsense_mediated_decay, 3 retained_intron, 2 protein_coding_CDS_not_defined

ENST00000284290, ENST00000438907, ENST00000441174, ENST00000452080, ENST00000473629, ENST00000491010, ENST00000529543, ENST00000530731, ENST00000531033, ENST00000531667, ENST00000900019, ENST00000900020, ENST00000934207, ENST00000960171

RefSeq mRNA: 1 — MANE Select: NM_032811 NM_032811

CCDS: CCDS8448

Canonical transcript exons

ENST00000441174 — 9 exons

Exon	Start	End
ENSE00001465426	124626473	124626609
ENSE00001658286	124632093	124635926
ENSE00002142749	124622864	124623233
ENSE00003481494	124630388	124630485
ENSE00003550064	124624931	124625001
ENSE00003589076	124626904	124627050
ENSE00003624242	124631275	124631417
ENSE00003656253	124625671	124625903
ENSE00003660299	124630745	124630855

Expression profiles

Bgee: expression breadth ubiquitous, 250 present calls, max score 95.38.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.1758 / max 258.3651, expressed in 1822 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
117377	27.9501	1821
117376	1.9507	1211
117378	0.2750	104

Top tissues by expression

253 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	95.38	gold quality
mucosa of stomach	UBERON:0001199	95.04	gold quality
small intestine Peyer’s patch	UBERON:0003454	94.38	gold quality
rectum	UBERON:0001052	94.37	gold quality
monocyte	CL:0000576	94.24	gold quality
leukocyte	CL:0000738	93.95	gold quality
right lung	UBERON:0002167	93.76	gold quality
vermiform appendix	UBERON:0001154	93.65	gold quality
body of pancreas	UBERON:0001150	93.63	gold quality
spleen	UBERON:0002106	93.59	gold quality
tibia	UBERON:0000979	93.51	gold quality
prefrontal cortex	UBERON:0000451	93.42	gold quality
upper lobe of left lung	UBERON:0008952	93.38	gold quality
body of stomach	UBERON:0001161	93.27	gold quality
minor salivary gland	UBERON:0001830	93.18	gold quality
left lobe of thyroid gland	UBERON:0001120	93.12	gold quality
left adrenal gland cortex	UBERON:0035825	93.10	gold quality
small intestine	UBERON:0002108	92.99	gold quality
right adrenal gland cortex	UBERON:0035827	92.93	gold quality
descending thoracic aorta	UBERON:0002345	92.83	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.81	gold quality
transverse colon	UBERON:0001157	92.78	gold quality
thoracic aorta	UBERON:0001515	92.78	gold quality
ascending aorta	UBERON:0001496	92.75	gold quality
left adrenal gland	UBERON:0001234	92.73	gold quality
right lobe of thyroid gland	UBERON:0001119	92.60	gold quality
right lobe of liver	UBERON:0001114	92.44	gold quality
right adrenal gland	UBERON:0001233	92.39	gold quality
thyroid gland	UBERON:0002046	92.36	gold quality
lower esophagus muscularis layer	UBERON:0035833	92.33	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

115 targeting TBRG1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-3646	100.00	73.56	5283
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-4666A-3P	99.96	71.71	3434
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-146A-5P	99.96	68.93	988
HSA-MIR-146B-5P	99.96	69.13	977
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-7153-5P	99.94	68.89	1006
HSA-MIR-539-5P	99.93	70.30	2855

Literature-anchored findings (GeneRIF, showing 5)

• novel protein with tumor suppressor-like behaviors and functional links to ARF-MDM2-p53 signaling (PMID:17110379)
• NIAM is a nuclear interactor of ARF and Mdm2 (PMID:18582208)
• Sructure of a fragment of TBRG1 was shown to encompasses two motifs. The FYRN and FYRC regions each form part of a single folded module (the FYR domain), which adopts a novel alpha + beta fold. (PMID:20506279)
• NIAM regulates 2 critical pathways that control p53 function and are altered in human cancers, implying an important role for NIAM in tumorigenesis. (PMID:24621507)
• In primary B-cell lymphoma NIAM-positive cases have significant lower levels of miR-155 as compared to NIAM-negative cases, suggesting that NIAM is regulated by miR-155 in primary B-cell lymphoma. (PMID:26497687)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	tbrg1	ENSDARG00000074996
mus_musculus	Tbrg1	ENSMUSG00000011114
rattus_norvegicus	Tbrg1	ENSRNOG00000023850
rattus_norvegicus	LOC100911055	ENSRNOG00000033891
drosophila_melanogaster	CG31111	FBGN0051111

Protein

Protein identifiers

Transforming growth factor beta regulator 1 — Q3YBR2 (reviewed: Q3YBR2)

Alternative names: Nuclear interactor of ARF and Mdm2

All UniProt accessions (4): Q3YBR2, E9PI10, E9PK87, F8W6N5

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a growth inhibitor. Can activate p53/TP53, causes G1 arrest and collaborates with CDKN2A to restrict proliferation, but does not require either protein to inhibit DNA synthesis. Redistributes CDKN2A into the nucleoplasm. Involved in maintaining chromosomal stability.

Subunit / interactions. Interacts with CDKN2A and MDM2.

Subcellular location. Nucleus.

Tissue specificity. Widely expressed at low levels in most tissues, with highest levels in pancreas, lung and liver. Expression is decreased in primary tumors including lung, liver, breast, pancreas and kidney carcinomas, chronic lymphocytic leukemia and diffuse large B-cell lymphoma.

Post-translational modifications. Ubiquitinated; mediated by MDM2 and leading to its subsequent proteasomal degradation.

Similarity. Belongs to the TBRG1 family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q3YBR2-1	1	yes
Q3YBR2-2	2
Q3YBR2-3	3

RefSeq proteins (1): NP_116200* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003888	FYrich_N	Conserved_site
IPR003889	FYrich_C	Conserved_site
IPR040092	TBRG1	Family

Pfam: PF05964, PF05965

UniProt features (23 total): strand 6, helix 6, domain 2, region of interest 2, modified residue 2, splice variant 2, initiator methionine 1, chain 1, sequence conflict 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
2WZO	X-RAY DIFFRACTION	1.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q3YBR2-F1	72.57	0.45

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 2, 10

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): GOBP_PROTEIN_STABILIZATION, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_PROTEIN_STABILITY, NKX22_01, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_PROTEIN_LOCALIZATION_TO_ORGANELLE, GOBP_PROTEIN_LOCALIZATION_TO_NUCLEUS, GOBP_DNA_REPLICATION, MARSON_BOUND_BY_FOXP3_STIMULATED, MARSON_BOUND_BY_FOXP3_UNSTIMULATED, GOBP_DNA_METABOLIC_PROCESS, chr11q24, GINESTIER_BREAST_CANCER_20Q13_AMPLIFICATION_DN, GOBP_PROTEIN_LOCALIZATION_TO_NUCLEOPLASM, GSE14415_INDUCED_TREG_VS_TCONV_DN

GO Biological Process (5): DNA replication (GO:0006260), negative regulation of cell population proliferation (GO:0008285), protein stabilization (GO:0050821), regulation of cell cycle (GO:0051726), protein localization to nucleoplasm (GO:1990173)

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA metabolic process	1
DNA biosynthetic process	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
regulation of protein stability	1
cell cycle	1
regulation of cellular process	1
protein localization to nucleus	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1182 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TBRG1	RABL6	Q3YEC7	774
TBRG1	ZNF740	Q8NDX6	626
TBRG1	REEP5	Q00765	624
TBRG1	ADAMTSL2	Q86TH1	599
TBRG1	TMSB10	P13472	578
TBRG1	FBN1	P35555	576
TBRG1	CDKN2A	P42771	524
TBRG1	ADAMTS10	Q9H324	506
TBRG1	GARNL3	Q5VVW2	480
TBRG1	INO80E	Q8NBZ0	474
TBRG1	CARNMT1	Q8N4J0	444
TBRG1	TSKU	Q8WUA8	439
TBRG1	GDPD5	Q8WTR4	423
TBRG1	GRAMD1B	Q3KR37	421
TBRG1	TGFB1	P01137	419

IntAct

37 interactions, top by confidence:

A	B	Type	Score
TBRG1	ZMYND19	psi-mi:“MI:0915”(physical association)	0.670
TBRG1	SMYD1	psi-mi:“MI:0915”(physical association)	0.560
TBRG1		psi-mi:“MI:0915”(physical association)	0.560
TBRG1	PMP22	psi-mi:“MI:0915”(physical association)	0.560
DNALI1	TBRG1	psi-mi:“MI:0915”(physical association)	0.560
KLF11	TBRG1	psi-mi:“MI:0915”(physical association)	0.560
TBRG1	HSPD1	psi-mi:“MI:0915”(physical association)	0.400
TBRG1	SNRPB	psi-mi:“MI:0915”(physical association)	0.400
TBRG1	YTHDC1	psi-mi:“MI:0915”(physical association)	0.400
Ruvbl1	AAR2	psi-mi:“MI:0914”(association)	0.350
RUVBL2	ASDURF	psi-mi:“MI:0914”(association)	0.350
TBRG1	APOD	psi-mi:“MI:0914”(association)	0.350
SMYD1	TBRG1	psi-mi:“MI:0915”(physical association)	0.000
ZMYND19	TBRG1	psi-mi:“MI:0915”(physical association)	0.000
	TBRG1	psi-mi:“MI:0915”(physical association)	0.000
TBRG1	fadB/acbP	psi-mi:“MI:0915”(physical association)	0.000
TBRG1		psi-mi:“MI:0915”(physical association)	0.000

BioGRID (23): TBRG1 (Two-hybrid), TBRG1 (Two-hybrid), TBRG1 (Two-hybrid), INO80E (Two-hybrid), TBRG1 (Affinity Capture-MS), TBRG1 (Affinity Capture-MS), TBRG1 (Affinity Capture-MS), TBRG1 (PCA), TBRG1 (Two-hybrid), ZMYND19 (Two-hybrid), TBRG1 (Proximity Label-MS), TBRG1 (Proximity Label-MS), YTHDC1 (Proximity Label-MS), TBRG1 (Affinity Capture-MS), UBR3 (Affinity Capture-MS)

ESM2 similar proteins: A0M8S4, A1L0Z0, B5DEB9, B5DF21, F5HSE3, O95155, P97496, Q07DX4, Q07DY4, Q07E41, Q0IHW3, Q108T9, Q15648, Q172G3, Q1LUT1, Q1LVF3, Q26622, Q2IBA2, Q2IBE6, Q2IBF7, Q2QLB3, Q2QLF8, Q32N92, Q3YBR2, Q5FWP2, Q5PRF9, Q5RES4, Q6DD45, Q6INP8, Q6IRB8, Q6IZA3, Q6P4L9, Q6P4R8, Q6PIJ4, Q7ZXT3, Q80TZ3, Q80XS6, Q8CBY1, Q8INR6, Q8MX88

Diamond homologs: Q3UB74, Q3YBR2, Q5PQK8, Q66IH2, Q6K431

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

73 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	1
Uncertain significance	61
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
996584	NM_032811.3(TBRG1):c.628G>A (p.Ala210Thr)	Likely pathogenic

SpliceAI

1390 predictions. Top by Δscore:

Variant	Effect	Δscore
11:124623179:G:GT	donor_gain	1.0000
11:124623230:GTTT:G	donor_gain	1.0000
11:124623234:G:GG	donor_gain	1.0000
11:124624902:T:G	acceptor_gain	1.0000
11:124624918:T:G	acceptor_gain	1.0000
11:124630386:A:AG	acceptor_gain	1.0000
11:124630386:AGTTT:A	acceptor_gain	1.0000
11:124630387:G:GA	acceptor_gain	1.0000
11:124630387:GTTT:G	acceptor_gain	1.0000
11:124630387:GTTTG:G	acceptor_gain	1.0000
11:124630468:GACTA:G	donor_gain	1.0000
11:124630486:G:GG	donor_gain	1.0000
11:124630856:G:GG	donor_gain	1.0000
11:124631270:T:TA	acceptor_gain	1.0000
11:124631271:GCAGT:G	acceptor_loss	1.0000
11:124631272:CAGT:C	acceptor_loss	1.0000
11:124631273:A:AC	acceptor_loss	1.0000
11:124631273:A:AG	acceptor_gain	1.0000
11:124631274:G:A	acceptor_loss	1.0000
11:124631274:G:GC	acceptor_gain	1.0000
11:124631274:GTT:G	acceptor_gain	1.0000
11:124631274:GTTAC:G	acceptor_gain	1.0000
11:124623191:G:GT	donor_gain	0.9900
11:124623232:TT:T	donor_gain	0.9900
11:124623232:TTGTG:T	donor_loss	0.9900
11:124623233:TG:T	donor_loss	0.9900
11:124623234:G:GA	donor_loss	0.9900
11:124623235:T:A	donor_loss	0.9900
11:124623236:G:GC	donor_loss	0.9900
11:124623238:G:C	donor_loss	0.9900

AlphaMissense

2682 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:124624940:G:C	A54P	0.999
11:124625688:T:C	L80P	0.998
11:124626925:T:C	F205L	0.998
11:124626927:T:A	F205L	0.998
11:124626927:T:G	F205L	0.998
11:124630792:G:A	G295E	0.998
11:124623205:T:C	L41P	0.997
11:124623217:C:A	A45D	0.997
11:124624937:G:C	A53P	0.997
11:124626605:G:A	G196E	0.997
11:124626964:A:C	S218R	0.997
11:124626966:T:A	S218R	0.997
11:124626966:T:G	S218R	0.997
11:124626971:G:C	R220P	0.997
11:124630819:T:C	L304P	0.997
11:124623216:G:C	A45P	0.996
11:124624936:T:A	N52K	0.996
11:124624936:T:G	N52K	0.996
11:124624941:C:A	A54D	0.996
11:124624958:G:C	A60P	0.996
11:124624965:T:C	L62P	0.996
11:124624999:A:C	R73S	0.996
11:124624999:A:T	R73S	0.996
11:124626604:G:A	G196R	0.996
11:124626604:G:C	G196R	0.996
11:124626605:G:T	G196V	0.996
11:124627018:T:C	C236R	0.996
11:124630388:T:C	F247L	0.996
11:124630390:T:A	F247L	0.996
11:124630390:T:G	F247L	0.996

dbSNP variants (sampled 300 via entrez): RS1000090925 (11:124630680 T>C), RS1000141555 (11:124624184 A>G), RS1000151876 (11:124634220 G>A), RS1000719933 (11:124632927 C>G), RS1000751215 (11:124632520 T>C), RS1001508638 (11:124635685 A>C,G,T), RS1001562395 (11:124635856 G>A), RS1001717680 (11:124628962 A>G), RS1002150573 (11:124621695 C>G,T), RS1002265625 (11:124635947 T>C), RS1002453009 (11:124627397 G>C), RS1002639251 (11:124636210 C>A), RS1002726644 (11:124629221 C>T), RS1003077726 (11:124622771 G>C), RS1003518170 (11:124632650 A>G)

Disease associations

OMIM: gene MIM:610614 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): intellectual disability (MONDO:0001071)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST006865_13	Bipolar disorder	6.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

28 total (human), top 28 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, decreases methylation, affects cotreatment, increases expression	3
Lead	affects expression, increases expression	2
Cyclosporine	increases expression	2
FR900359	increases phosphorylation	1
methylmercuric chloride	decreases expression, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
sodium arsenite	increases expression	1
di-n-butylphosphoric acid	affects expression	1
perfluorooctane sulfonic acid	increases expression	1
pentabromodiphenyl ether	increases expression	1
perfluoro-n-nonanoic acid	increases expression	1
14-deoxy-11,12-didehydroandrographolide	increases expression	1
NSC 689534	affects binding, increases expression	1
3-(2-hydroxy-4-(2-methylnonan-2-yl)phenyl)cyclohexan-1-ol	increases expression	1
Sunitinib	increases expression	1
Vorinostat	decreases expression	1
Caffeine	increases phosphorylation	1
Carbamazepine	affects expression	1
Copper	affects binding, increases expression	1
Dimethyl Sulfoxide	increases expression	1
Doxorubicin	decreases expression	1
Hydralazine	affects cotreatment, increases expression	1
Ketoconazole	increases expression	1
Methyl Methanesulfonate	increases expression	1
Smoke	decreases expression	1
Dihydrotestosterone	increases expression	1
Aflatoxin B1	decreases methylation	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

197 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT03479476	PHASE2/PHASE3	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome
NCT02616796	PHASE1/PHASE2	COMPLETED	Effects of Social Gaze Training on Brain and Behavior in Fragile X Syndrome
NCT06860672	EARLY_PHASE1	RECRUITING	Clinical Trial of the Dual Vector Base Editor for the Treatment of the CHD3-R1025W Mutation
NCT00597948	Not specified	COMPLETED	Healthy Lifestyles for People With Intellectual Disabilities
NCT01087320	Not specified	RECRUITING	Genome Medical Sequencing for Gene Discovery
NCT01652963	Not specified	UNKNOWN	Picture-based Computerised Assessment and Training of Cognitive Behaviour Therapy Skills
NCT01695395	Not specified	COMPLETED	Mental Health Care Provision for Adults With Intellectual Disability and a Mental Disorder
NCT01867554	Not specified	COMPLETED	Research and Characterization of New Genes Involved in Intellectual Disability
NCT01915381	Not specified	COMPLETED	Improving Adherence Healthy Lifestyle With a Smartphone Application Based on Adults With Intellectual Disabilities
NCT01988623	Not specified	COMPLETED	Pivotal Response Treatment for Individuals With Intellectual Disabilities
NCT02099773	Not specified	COMPLETED	Support Staff-client Interactions With Augmentative and Alternative Communication
NCT02136849	Not specified	COMPLETED	Inter-regional Project of the Great Western Exploration Approach for Exome Molecular Causes Severe Intellectual Disability Isolated or Syndromic
NCT02225041	Not specified	COMPLETED	Sedation Strategy and Cognitive Outcome After Critical Illness in Early Childhood
NCT02414438	Not specified	COMPLETED	Establishing the Clinical Utility of First StepDx PLUS and NextStepDx PLUS Study
NCT02451761	Not specified	COMPLETED	Apparently Balanced Chromosomal Translocation/ Next-generation Sequencing/ Intellectual Disability
NCT02461420	Not specified	ACTIVE_NOT_RECRUITING	Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome
NCT02461459	Not specified	ACTIVE_NOT_RECRUITING	Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)
NCT02486081	Not specified	COMPLETED	Development and Application-Smart Football for Movement Evaluation and Training in the Special Education Population
NCT02504502	Not specified	COMPLETED	Enhancing Genomic Laboratory Reports to Enhance Communication and Empower Patients
NCT02513277	Not specified	COMPLETED	Diabetes Screening & Prevention for People With Learning (Intellectual) Disabilities:STOP Diabetes Study
NCT02561754	Not specified	COMPLETED	Weight Management for Adolescents With IDD
NCT02591446	Not specified	COMPLETED	Transcranial Magnetic Stimulation Studies in Autism Spectrum Disorders
NCT02714868	Not specified	COMPLETED	Evaluation of Project TEAM (Teens Making Environmental and Activity Modifications)
NCT02721394	Not specified	UNKNOWN	FCT With Young Children With ID in the UK: A Feasibility Project V.1
NCT02746614	Not specified	COMPLETED	Psychomotor Therapy Effects in Adaptive Behavior and Motor Proficiency in Intellectual Disability
NCT02836405	Not specified	COMPLETED	TMS for the Investigation of Brain Plasticity in Autism Spectrum Disorders